Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

22-08-2017 | CNS metastases | Article

Survival and level of care among breast cancer patients with brain metastases treated with whole brain radiotherapy

Journal: Breast Cancer Research and Treatment

Authors: Gabriella Frisk, Beatrice Tinge, Sara Ekberg, Sandra Eloranta, L. Magnus Bäcklund, Elisabet Lidbrink, Karin E. Smedby

Publisher: Springer US

Login to get access

Abstract

Purpose

The benefit of whole brain radiotherapy (WBRT) for late stage breast cancer patients with brain metastases has been questioned. In this study we evaluated survival and level of care (hospital or home) following WBRT in a population-based cohort by personal and tumor characteristics.

Methods

We identified 241 consecutive patients with breast cancer and brain metastases receiving WBRT in Stockholm, Sweden, 1999–2012. Through review of medical records, we collected data on prognostic determinants including level of care before and after WBRT. Survival was estimated using Cox regression, and odds ratios (OR) of not coming home using logistic regression.

Results

Median age at WBRT was 58 years (range 30--–88 years). Most patients (n = 212, 88%) were treated with 4 Gray × 5. Median survival following WBRT was 2.9 months (interquartile range 1.1–6.6 months), and 57 patients (24%) were never discharged from hospital. Poor performance status and triple-negative tumors were associated with short survival (WHO 3–4 median survival 0.9 months, HR = 5.96 (3.88–9.17) versus WHO 0–1; triple-negative tumors median survival 2.0 months, HR = 1.87 (1.23–2.84) versus Luminal A). Poor performance status and being hospitalized before WBRT were associated with increased ORs of not coming home whereas cohabitation with children at home was protective.

Conclusion

Survival was short following WBRT, and one in four breast cancer patients with brain metastases could never be discharged from hospital. When deciding about WBRT, WHO score, level of care before WBRT, and the patient’s choice of level of care in the end-of-life period should be considered.
Literature
1.
Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617CrossRefPubMed
2.
Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872CrossRefPubMed
3.
Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648–1655CrossRefPubMed
4.
Frisk G, Svensson T, Backlund LM et al (2012) Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer 106:1850–1853CrossRefPubMedPubMedCentral
5.
Lin NU, Amiri-Kordestani L, Palmieri D et al (2013) CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res 19:6404–6418CrossRefPubMed
6.
Sperduto PW, Kased N, Roberge D et al (2013) The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol 112:467–472CrossRefPubMed
7.
Liu Y, Alexander BM, Chen YH et al (2015) Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases. J Neurooncol 124:429–437CrossRefPubMed
8.
Bergh (2014) Nationellt vårdprogram för bröstcancer. Nationellt vårdprogram för bröstcancer
9.
Fontanella C, De Carlo E, Cinausero M et al (2016) Central nervous system involvement in breast cancer patients: is the therapeutic landscape changing too slowly? Cancer Treat Rev 46:80–88CrossRefPubMed
10.
Nieder C, Norum J, Dalhaug A et al (2013) Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors. Clin Exp Metastasis 30:723–729CrossRefPubMed
11.
Feyer P, Sautter-Bihl ML, Budach W et al (2010) DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol 186:63–69CrossRefPubMed
12.
Beccaro M, Costantini M, Giorgi Rossi P et al (2006) Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC). J Epidemiol Community Health 60:412–416CrossRefPubMedPubMedCentral
13.
Nilsson J, Blomberg C, Holgersson G et al (2017) End-of-life care: where do cancer patients want to die? A systematic review. Asia Pac J Clin Oncol. doi:10.​1111/​ajco.​12678 PubMed
14.
Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500CrossRefPubMed
15.
Noordijk EM, Vecht CJ, Haaxma-Reiche H et al (1994) The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29:711–717CrossRefPubMed
16.
Mintz AH, Kestle J, Rathbone MP et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470–1476CrossRefPubMed
17.
Fokstuen T, Wilking N, Rutqvist LE et al (2000) Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat 62:211–216CrossRefPubMed
18.
Broadbent AM, Hruby G, Tin MM et al (2004) Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiother Oncol 71:259–265CrossRefPubMed
19.
Borgelt B, Gelber R, Kramer S et al (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1–9CrossRefPubMed
20.
Tsao MN, Lloyd N, Wong RK et al (2012) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 18(4):CD003869
21.
Edwards A, Gerard G (1998) The management of cerebral metastases. Eur J Pall Care 5:7–11
22.
Ogawa K, Yoshii Y, Nishimaki T et al (2008) Treatment and prognosis of brain metastases from breast cancer. J Neurooncol 86:231–238CrossRefPubMed
23.
Hall WA, Djalilian HR, Nussbaum ES et al (2000) Long-term survival with metastatic cancer to the brain. Med Oncol 17:279–286CrossRefPubMed
24.
Nussbaum ES, Djalilian HR, Cho KH et al (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78:1781–1788CrossRefPubMed
25.
Chong JU, Ahn SG, Lee HM et al (2015) Local control of brain metastasis: treatment outcome of focal brain treatments in relation to subtypes. J Breast Cancer 18:29–35CrossRefPubMedPubMedCentral
26.
Subbiah IM, Lei X, Weinberg JS et al (2015) Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol 33:2239–2245CrossRefPubMedPubMedCentral
27.
Bröstcancerregistret SFN (2014) Årsrapport RAPPORT FRÅN NATIONELLA BRÖSTCANCERREGISTRET 2014
28.
Gu X, Cheng W, Cheng M et al (2015) The preference of place of death and its predictors among terminally ill patients with cancer and their caregivers in China. Am J Hosp Palliat Care 32:835–840CrossRefPubMed
Image Credits